^
Association details:
| Biomarker: | ASXL1 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + decitabine (DNMT inhibitor) + Vesanoid (tretinoin) (Cytotoxic T lymphocyte stimulant, Telomerase inhibitor, Retinoic acid receptor agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical Efficacy Analysis of the Low-Dose Decitabine in Combination with Cytarabine, All-Trans Retinoic Acid and Granulocyte Colony-Stimulating Factor for Patients with MDS-EB
Published date:
11/04/2021
Excerpt:
In this study, we evaluated the tolerance and efficacy of the combination of low-dose decitabine, cytarabine, all-trans retinoic acid and granulocyte colony-stimulating factor (DLAAG) for MDS-EB patients...we noted the complete response in patients with ASXL1, TP53 mutations or WT1 overexpression despite the concomitant presence of complex cytogenetic at diagnosis...
DOI:
10.1182/blood-2021-144631
Trial ID:
